TFF Pharmaceuticals, Inc. (TFFP)
Largest Insider Buys in Sector
TFFP Stock Price History Chart
TFFP Stock Performance
About TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation …
Insider Activity of TFF Pharmaceuticals, Inc.
Over the last 12 months, insiders at TFF Pharmaceuticals, Inc. have bought $0 and sold $0 worth of TFF Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at TFF Pharmaceuticals, Inc. have bought $428,208 and sold $8.66M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 600,000 shares for transaction amount of $150,000 was made by Weisman Harlan F (President and CEO) on 2023‑08‑15.
List of Insider Buy and Sell Transactions, TFF Pharmaceuticals, Inc.
| 2023-08-16 | Sale | 10 percent owner | 1,000 0.0029% | $0.39 | $392 | -29.30% | ||
| 2023-08-15 | Sale | 10 percent owner | 215,000 0.6319% | $0.44 | $94,041 | -36.00% | ||
| 2023-08-15 | President and CEO | 600,000 1.0079% | $0.25 | $150,000 | -36.00% | |||
| 2023-08-15 | Chief Medical Officer | 120,000 0.2016% | $0.25 | $30,000 | -36.00% | |||
| 2023-08-15 | director | 40,000 0.0672% | $0.25 | $10,000 | -36.00% | |||
| 2023-08-15 | director | 20,000 0.0336% | $0.25 | $5,000 | -36.00% | |||
| 2023-08-15 | Chief Financial Officer | 20,000 0.0336% | $0.25 | $5,000 | -36.00% | |||
| 2023-08-15 | director | 20,000 0.0336% | $0.25 | $5,000 | -36.00% | |||
| 2023-03-10 | President and CEO | 150,000 0.5044% | $0.88 | $131,835 | -50.14% | |||
| 2023-03-10 | director | 13,000 0.0399% | $0.80 | $10,433 | -50.14% | |||
| 2023-03-10 | Chief Financial Officer | 12,000 0.0362% | $0.79 | $9,457 | -50.14% | |||
| 2023-03-10 | Chief Medical Officer | 15,000 0.0471% | $0.82 | $12,300 | -50.14% | |||
| 2022-12-15 | President and CEO | 50,000 0.1733% | $1.06 | $53,000 | -54.90% | |||
| 2022-11-22 | director | 43,470 0.1158% | $1.15 | $49,991 | -61.81% | |||
| 2022-09-29 | Sale | 40,255 0.1589% | $4.29 | $172,694 | -83.95% | |||
| 2022-05-18 | 4,615 0.02% | $5.50 | $25,383 | -72.95% | ||||
| 2022-05-16 | 24,600 0.1035% | $5.08 | $124,968 | -69.75% | ||||
| 2022-05-16 | President and CEO | 16,000 0.0633% | $4.78 | $76,480 | -69.75% | |||
| 2022-05-16 | 3,000 0.0113% | $4.54 | $13,620 | -69.75% | ||||
| 2022-05-16 | 2,500 0.0098% | $4.74 | $11,850 | -69.75% |
Insider Historical Profitability
| Weisman Harlan F | President and CEO | 814615 23.5028% | $1.67 | 6 | 0 | <0.0001% |
| Fletcher Aaron G.L. | director | 143470 4.1393% | $1.67 | 10 | 0 | +98.86% |
| Mikhak Zamaneh | Chief Medical Officer | 135000 3.8949% | $1.67 | 2 | 0 | <0.0001% |
| MILLS ROBERT S | director | 55980 1.6151% | $1.67 | 2 | 4 | |
| ROCAMBOLI STEPHEN | director | 36000 1.0386% | $1.67 | 3 | 3 | <0.0001% |